Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$75.99

-0.65 (-0.85%)

, BIIB

Biogen

$318.11

-0.21 (-0.07%)

09:07
11/23/16
11/23
09:07
11/23/16
09:07

On The Fly: Pre-market Movers

UP AFTER EARNINGS: Deere (DE), up 10%. DOWN AFTER EARNINGS: HP Inc. (HPQ), down 4%... Hewlett Packard Enterprise (HPE), down 2%... Nimble Storage (NMBL), down 11%. ALSO LOWER: Eli Lilly (LLY), down 14% after solanezumab did not meet the primary endpoint in a phase 3 study in people with mild dementia due to Alzheimer's disease. Biogen (BIIB), which is studying an alternate Alzheimer's drug, aducanimab, is down over 8% and Axovant Sciences (AXON), which is also developing its own drug for the treatment of patients with Alzheimer's disease, is down 8.5%... Juno Therapeutics (JUNO), down 30% after the company announced that it has voluntarily placed on hold the Phase II clinical trial of JCAR015, known as the "ROCKET" trial, after two patients suffered cerebral edema earlier this week and subsequently died. Other companies working on "CAR-T" therapies, a new class of oncology drugs that reengineer a patient's own cells to attack the disease, including Kite Pharma (KITE), ZIOPHARM Oncology (ZIOP) and bluebird bio (BLUE), are falling in pre-market trading as well... Enable Midstream (ENBL), down 11.75% after the company's 10M share secondary offering of stock priced at $14 per share.

LLY

Eli Lilly

$75.99

-0.65 (-0.85%)

BIIB

Biogen

$318.11

-0.21 (-0.07%)

AXON

Axovant Sciences

$13.45

-0.03 (-0.22%)

JUNO

Juno Therapeutics

$29.88

-1.56 (-4.96%)

DE

Deere

$92.01

-0.29 (-0.31%)

KITE

Kite Pharma

$51.69

-1.99 (-3.71%)

ZIOP

Ziopharm

$6.14

-0.27 (-4.21%)

BLUE

bluebird bio

$60.95

-1.55 (-2.48%)

ENBL

Enable Midstream

$16.09

-0.26 (-1.59%)

HPQ

HP Inc.

$15.95

-0.05 (-0.31%)

HPE

HP Enterprise

$22.87

-0.25 (-1.08%)

NMBL

Bought by HPE

$9.24

0.15 (1.65%)

  • 23

    Nov

  • 28

    Nov

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 23

    Nov

LLY Eli Lilly
$75.99

-0.65 (-0.85%)

11/23/16
SBSH
11/23/16
NO CHANGE
Target $305
SBSH
Neutral
Citi pegs potential Biogen downside to $287 on Lilly failure
In a research note dated yesterday, Citi analyst Robyn Karnauskas said shares of Biogen (BIIB) could fall to $286 should Eli Lilly's (LLY) Alzheimer's drug solanezumab fail in its Phase 3 study. After Lilly reported this morning that the trial failed, shares of Biogen are down 6%, or $18.60, to $299.51 in pre-market trading. Shares of Lilly are down 14%, or $10.77, to $65.22. Karnauskas estimated the downside range of Biogen on a failed solanezumab study at $287-$306. The analyst has a Neutral rating on Biogen.
11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Overweight
Piper's Schimmer proclaims amyloid hypothesis is not dead
Piper Jaffray analyst Joshua Schimmer says the failure of Eli Lilly's (LLY) solanezumab is not the final nail in the amyloid hypothesis coffin. Biogen (BIIB) and Eisai's aducanimab study is the most potent approach for amyloid lowering, Schimmer tells investors in a research note. He points out that he was skeptical whether solanezumab's effect was adequate. "Our view of Alzheimer's for amyloid is informed not so much by the extremely sloppy science in that disease, but by consistent cause/effect signals across other amyloidosis," Schimmer writes. He believes today's selloff in shares of Biogen "creates some breathing room." The analyst recommends looking to build a position in Biogen after the stock settles down. Schimmer reiterates an Overweight rating on the shares with a $335 price target. The stock is down 8%, or $24.41, to $293.70 in pre-market trading.
11/23/16
JPMS
11/23/16
NO CHANGE
Target $85
JPMS
Overweight
JPMorgan sees 'attractive opportunity' amid Eli Lilly selloff
JPMorgan analyst Chris Schott lowered his price target for Eli Lilly to $85 from $95 after the phase III trial of solanezumab missed on both primary and secondary endpoints. Beyond solanezumab, Lilly has a diverse range of new product opportunities that support 5% sales and mid-teens earnings growth, Schott tells investors in a research note. With the shares down 13% to $65.81 in pre-market trading, the analyst sees an "attractive opportunity." He keeps an Overweight rating on Lilly.
11/23/16
JEFF
11/23/16
NO CHANGE
Target $100
JEFF
Buy
Eli Lilly still expects to grow revenue, says Jefferies
Jefferies analyst Jeffrey Holford says that while the solanezumab Phase III trial failure is disappointing, Eli Lilly management expects to grow revenue between 2015 and 2020 while expanding margins. Further, the company is still pursuing the Alzheimer's indication though a number of other programs, Holford tells investors in a research note. The analyst previously estimated a negative solanezumab trial outcome could see the stock down $12. Shares of Lilly are currently down $10.19 to $65.80 in pre-market trading. Holford keeps a Buy rating on Lilly with a $100 price target.
BIIB Biogen
$318.11

-0.21 (-0.07%)

11/09/16
PIPR
11/09/16
NO CHANGE
PIPR
Piper sees improving environment for Biopharma M&A
The biotech sector is seeing a "massive relief rally" given the "surprise trifecta" of a Republican sweep, the voting down of Prop 61 in California and U.S. dollar weakness, Piper Jaffray analyst Joshua Schimmer tells investors in a research note. The door is now open to discuss potential repatriation of cash outside the U.S., which could be a green light on mergers and acquisitions, the analyst adds. He points out that Amgen (AMGN) and Gilead (GILD) hold the most overseas cash, with Celgene (CELG) and Biogen (BIIB) holding several billion as well. Schimmer believes the broader environment may be improving for M&A. He cautions, though, that the election of Trump does not remove the "major drug pricing overhang question."
11/09/16
RBCM
11/09/16
NO CHANGE
RBCM
Biotech stocks should be bought on post-election decline, says RBC Capital
RBC Capital recommends buying biotech stocks today on weakness. The firm notes that stocks usually rebound after they drop due to political events that don't affect their fundamentals, and it believes that the decline in biotech stocks today is in that category. The firm says that President-elect Trump probably won't focus on drug prices or Medicare reform. It adds that biotech companies should benefit from the fact that Congress will stay in GOP hands and the apparent failure of California's Proposition 61 initiative. The firm identifies Celgene (CELG), Biogen (BIIB), Vertex (VRTX), BioMarin (BMRN), and Prothena (PRTA) as its favorite names in the sector.
AXON Axovant Sciences
$13.45

-0.03 (-0.22%)

09/22/16
JMPS
09/22/16
NO CHANGE
JMPS
Axovant Sciences weakness an opportunity, says JMP Securities
09/22/16
CHDN
09/22/16
NO CHANGE
Target $8
CHDN
Sell
Recent failures of 5-HT6 competitors reinforce Axovant risks, says Chardan
After Lundbeck reported that its 5-HT6 antagonist, idalopirdine, did not meet the primary endpoint in the first of three phase III studies in mild-to-moderate Alzheimer's disease patients, Chardan analyst Gbola Amusa noted that this is the second recent failure of a mid-to-late-stage 5-HT6 antagonist coming on the heels of Pfizer's (PFE) prior miss. Amusa anticipates that some in the market will see limited read-across from Lundbeck to Axovant (AXON), but he thinks Pfizer's and Lundbeck's setbacks reinforce the risks for the 5-HT6 antagonist class in Alzheimer's. The analyst reiterates his Sell rating and $8 price target on Axovant shares.
09/22/16
HCWC
09/22/16
NO CHANGE
Target $35
HCWC
Buy
No read-through from idalopirdine to Axovant RVT-101, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein notes that Lundbeck announced that its idalopirdine missed its primary and secondary endpoints in the STARSHINE Phase 3 study in mild/moderate Alzheimer's disease. However, Fein says that idalopirdine miss does not shake his confidence in Axovant's RVT-101 as he believes Lundbeck may have simply not been able to dose idalopirdine high enough in the Phase 3 program, which minimizes read-through to Axovant's MINDSET Phase 3 study. He continues to believe that Axovant's own experimental Alzheimer's therapy is well positioned for a win. Fein reiterates a Buy rating and $35 price target on Axovant's shares. In afternoon trading, Axovant's stock has dropped almost 12% to $15.31 per share.
09/23/16
PIPR
09/23/16
NO CHANGE
Target $32
PIPR
Overweight
Axovant Sciences selloff provides entry point, says Piper Jaffray
Piper Jaffray analyst Charles Duncan believes yesterday's selloff in shares of Axovant Sciences provides an entry point into the name. Lundbeck's announcement that its first Phase III data with idalopirdine in Alzheimer's missed the primary endpoint does not have predictive value for the Axovant's ongoing RVT-101 Phase III study, Duncan tells investors in a research note. The analyst sees "several key differences" between the two candidates and Phase III programs. He believes RVT-101 is the best-in-class 5-HT6 candidate and thinks its MINDSET trial is well designed to show clinical benefit. Duncan reiterates an Overweight rating on Axovant with a $32 price target.
JUNO Juno Therapeutics
$29.88

-1.56 (-4.96%)

11/03/16
BTIG
11/03/16
UPGRADE
BTIG
Neutral
Juno Therapeutics upgraded to Neutral from Sell at BTIG
09/27/16
LEER
09/27/16
NO CHANGE
LEER
Outperform
Kite's ZUMA-1 interim data incrementally positive for Juno, says Leerink
Leerink analyst Michael Schmidt says Kite Pharma's (KITE) top-line interim results from its pivotal ZUMA-1 trial of anti-CD19 CAR-T product KTE-C19 in patients with chemorefractory diffuse large B-cell lymphoma, or DLBCL, are incrementally positive for Juno Therapeutics (JUNO). While Juno is roughly one year behind Kite in DLBCL, the analyst believes its JCAR017 holds the promise to have a compelling safety/efficacy profile in lymphoma and Acute Lymphoblastic Leukemia. He reiterates an Outperform rating on Juno's shares.
11/04/16
BTIG
11/04/16
UPGRADE
BTIG
Neutral
Juno Therapeutics upgraded to Neutral from Sell at BTIG
BTIG analyst Dane Leone upgraded Juno Therapeutics (JUNO) to Neutral from Sell citing valuation following the ASH abstract release showed similar response rates for JCAR017 versus Kite's (KITE) KTE-C19 in the treatment of patients with Diffuse Large B-Cell Lymphoma.
11/10/16
RHCO
11/10/16
NO CHANGE
RHCO
Juno Therapeutics drug could deliver best in class data, says SunTrust
SunTrust analyst Peter Lawson says that Juno's non-Hodgkin lymphoma,treatment, JCAR017, could deliver best in class data at ASH. The analyst reiterates a $48 price target and a Buy rating on the shares.
DE Deere
$92.01

-0.29 (-0.31%)

10/31/16
10/31/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ford (F) upgraded to Neutral from Underperform at Daiwa. 2. Chevron (CVX) upgraded to Conviction Buy from Neutral at Goldman with analyst Neil Mehta saying that after a decade of relatively flat production, the company is positioned for "strong volume improvement." 3. Fossil (FOSL) upgraded to Mixed from Negative at OTR Global with the firm saying checks indicate the response to Michael Kors (KORS) watches has been strong. 4. ADTRAN (ADTN) upgraded to Outperform from Market Perform at Northland with analyst Tim Savageaux citing the share pullback over merger concerns of its top customer CenturyLink (CTL). 5. Deere (DE) upgraded to Outperform from Neutral at Baird with analyst Mircea Dobre saying that North American large ag equipment is back to multi-decade lows and there is a sign of demand emerging outside the U.S. and there are meaningful cost savings in the pipeline. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/11/16
DBAB
11/11/16
NO CHANGE
Target $102
DBAB
Buy
Deustche says infrastructure upside not fully priced into Machinery names
Deutsche Bank analyst Nicole DeBlase expects infrastructure stimulus to be more of a 2018 "earnings tailwind" with legislation unlikely until the spring of 2017 at the earliest. She's skeptical that the rally in Machinery stocks can continue for an extended amount of time, but feels only 50% of the total benefit has been priced in, to date. Caterpillar (CAT) is the best way to play a U.S. infrastructure stimulus, DeBlase tells investors in a research note. She raised her price target for the shares to $102 from $95. The analyst also raised her price target for Buy-rated Oshkosh (OSK) to $72 from $65, for Hold-rated Deere (DE) to $95 from $90 and for Sell-rated CNH Industrial (CNHI) to $7.20 from $6.24.
10/31/16
BARD
10/31/16
UPGRADE
Target $100
BARD
Outperform
Deere upgraded to Outperform at Baird
As reported previously, Baird analyst Mircea Dobre raised his rating on Deere to Outperform from Neutral, noting that North American large ag equipment is back to multi-decade lows and there is a sign of demand emerging outside the U.S. and there are meaningful cost savings in the pipeline. Dobre reiterated his Outperform rating and raised his price target to $100 from $86 on Deere shares.
10/31/16
BARD
10/31/16
UPGRADE
BARD
Outperform
Deere upgraded to Outperform from Neutral at Baird
KITE Kite Pharma
$51.69

-1.99 (-3.71%)

10/10/16
ADAM
10/10/16
NO CHANGE
Target $75
ADAM
Buy
Kite Pharma BLA filing still expected by year end, says Canaccord
Canaccord analyst John Newman noted Kite Pharma released 12 month update on Zuma-1 Phase 1, which showed durable efficacy and is encouraging despite coming from a small patient group. The analyst saw the release as a continuation of positive trends and expects a BLA filing by the end of 2016. Newman reiterated his Buy rating and $75 price target on Kite Pharma shares.
11/21/16
HCWC
11/21/16
INITIATION
Target $78
HCWC
Buy
Kite Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Kite Pharma with a Buy rating and $78 price target. While the competition for Chimeric Antigen Receptor T-cells is intense, Kite should have a big first-mover advantage with KTE-C19, Davis tells investors in a research note.
11/10/16
RBCM
11/10/16
NO CHANGE
RBCM
Kite Pharma weakness creates buying opportunity, says RBC Capital
After Kite's stock fell recently, RBC Capital analyst Michael Yee blames the pullback on macro worries about the biotech sector and a number of "short-term questions," about several issues, including upcoming ASH data, new durability data expected next quarter, and questions about the FDA's view of its drug. However, the analyst thinks that the company's comments indicate that its talks with the FDA are going well, and he says he remains upbeat on the company's pipeline. He expects "a lot" of concerns about the company to be mitigated in the next three to six m,months, as he thinks that it will report positive data in the near to medium term.The analyst keeps an $85 price target and an Outperform rating on the shares.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
ZIOP Ziopharm
$6.14

-0.27 (-4.21%)

12/04/15
12/04/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Affimed Therapeutics (AFMD) initiated with an Outperform at Wells Fargo... American Farmland (AFCO) initiated with an Outperform at Raymond James... Amgen (AMGN) initiated with a Market Perform at Wells Fargo... Applied Genetic (AGTC) initiated with an Outperform at Wells Fargo... BCE (BCE) initiated with a Buy at Goldman... Capital Product (CPLP) initiated with a Buy at Janney Capital... Celestica (CLS) initiated with a Neutral at B. Riley... Colfax (CFX) initiated with a Perform at Oppenheimer... Dimension Therapeutics (DMTX) initiated with an Outperform at Wells Fargo... Dover (DOV) initiated with a Perform at Oppenheimer... Fate Therapeutics (FATE) initiated with an Outperform at Wells Fargo... FibroGen (FGEN) initiated with a Buy at Citi... Finish Line (FINL) initiated with a Hold at BB&T... Five Prime (FPRX) resumed with an Outperform at Wells Fargo... Foot Locker (FL) initiated with a Buy at BB&T... GWG Holdings (GWGH) initiated with a Buy at Roth Capital... General Growth (GGP) initiated with an Outperform at Boenning & Scattergood... GigOptix (GIG) initiated with a Buy at Sterne Agee CRT... Halozyme (HALO) initiated with an Outperform at Wells Fargo... Hasbro (HAS) initiated with a Hold at Jefferies... Infinera (INFN) initiated with an Outperform at Raymond James... Inphi (IPHI) initiated with a Buy at Sterne Agee CRT... Inter Parfums (IPAR) initiated with an Overweight at KeyBanc... Intercept (ICPT) initiated with a Market Perform at Wells Fargo... Isis Pharmaceuticals (ISIS) initiated with an Outperform at Wells Fargo... LinkedIn (LNKD) initiated with a Buy at Nomura... Macerich (MAC) initiated with an Outperform at Boenning & Scattergood... Markit (MRKT) initiated with a Hold at Cantor... Mattel (MAT) initiated with a Buy at Jefferies... Maximus (MMS) initiated with a Buy at Stifel... MyoKardia (MYOK) initiated with an Outperform at Wells Fargo... Nimble Storage (NMBL) initiated with an Overweight at JPMorgan... OncoMed (OMED) initiated with an Outperform at Wells Fargo... Patriot National (PN) initiated with a Buy at Compass Point... Pennsylvania REIT (PEI) initiated with a Neutral at Boenning & Scattergood... Pixelworks (PXLW) initiated with a Buy at Craig-Hallum... Qualcomm (QCOM) initiated with an Overweight at Pacific Crest... Regeneron (REGN) initiated with an Outperform at Wells Fargo... Regulus (RGLS) initiated with an Outperform at Wells Fargo... Rogers Communications (RCI) initiated with a Neutral at Goldman... Rouse Properties (RSE) initiated with a Neutral at Boenning & Scattergood... Sangamo (SGMO) initiated with an Outperform at Wells Fargo... Sanmina (SANM) initiated with a Buy at B. Riley... Simon Property (SPG) initiated with an Outperform at Boenning & Scattergood... TELUS (TU) initiated with a Neutral at Goldman... TESARO (TSRO) initiated with an Outperform at Wells Fargo... Tokai Pharmaceuticals (TKAI) initiated with an Outperform at Wells Fargo... Vitae Pharmaceuticals (VTAE) initiated with an Outperform at Wells Fargo... ZIOPHARM (ZIOP) initiated with an Underperform at Wells Fargo... bluebird bio (BLUE) initiated with an Outperform at Wells Fargo.
06/02/16
RAJA
06/02/16
INITIATION
RAJA
Market Perform
ZIOPHARM initiated with a Market Perform at Raymond James
07/15/16
JMPS
07/15/16
NO CHANGE
Target $42
JMPS
Outperform
JMP says ZIOPHARM trial death doesn't read through to other Intrexon programs
JMP Securities analyst Jason Butler said he views the patient death in ZIOPHARM's (ZIOP) Ad-RTS-IL-12 GBM trial as "possibly or even likely due to the study drug" and acknowledges the need for caution regarding the potential safety concerns of Ad-RTS-IL-12. However, while the trial death raises questions, Butler contends it has no read through to partner Intrexon's (XON) broader oncology programs. The analyst, who notes there are multiple other programs in or entering the clinic under the collaborations between ZIOPHARM and Intrexon, keeps an Outperform rating and $42 price target on Intrexon shares.
08/10/16
WELS
08/10/16
UPGRADE
WELS
Market Perform
ZIOPHARM upgraded to Market Perform from Underperform at Wells Fargo
Wells Fargo analyst Jim Birchenough upgraded ZIOPHARM Oncology to Market Perform citing valuation following the company's Q2 results. The analyst keeps a $5-$8 price target range for the shares.
BLUE bluebird bio
$60.95

-1.55 (-2.48%)

11/11/16
11/11/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aegerion (AEGN) resumed with a Neutral at JPMorgan. 2. Lamb Weston (LW) initiated with a Buy at Stifel, initiated with an Overweight at Barclays, and an Equal Weight at Morgan Stanley. 3. bluebird bio (BLUE) initiated with a Market Perform at BMO Capital. 4. Alder Biopharmaceuticals (ALDR) initiated with an Outperform at BMO Capital. 5. ACADIA (ACAD) initiated with a Neutral at Goldman. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/10/16
BMOC
11/10/16
INITIATION
Target $61
BMOC
Market Perform
bluebird bio initiated with a Market Perform at BMO Capital
Analyst Matthew Luchini initiated bluebird with a Market Perform and a $61 price target.
11/10/16
BMOC
11/10/16
INITIATION
Target $61
BMOC
Market Perform
bluebird bio initiated with a Market Perform at BMO Capital
BMO Capital initiated bluebird bio with a Market Perform rating and $61 price target.
11/04/16
MAXM
11/04/16
NO CHANGE
Target $57
MAXM
Buy
bluebird bio price target lowered to $57 from $100 at Maxim
After bluebird released abstracts to be presented at the American Society of Hematology meeting in December, Maxim analyst Jason McCarthy said the "long-awaited" data for the next seven patients in the sickle cell study failed to impress, noting that the median vector copy number of corrected hemoglobin is low. Given expectations for longer timelines to get to Proof of Concept data in sickle cell, McCarthy has pushed back his expectations for a commercial launch in sickle cell to 2022 from 2020 and lowered his price target to $57 from $100, but given the potential in other program and the current valuation, he keeps a Buy rating on bluebird shares.
ENBL Enable Midstream
$16.09

-0.26 (-1.59%)

09/19/16
GSCO
09/19/16
UPGRADE
GSCO
Neutral
Enable Midstream upgraded to Neutral from Sell at Goldman
Goldman analyst Theodore Durbin upgraded Enable Midstream citing more balanced risk/reward. The analyst raised his price target to $24 from $20 on shares.
10/07/16
WOLF
10/07/16
INITIATION
WOLF
Peer Perform
Enable Midstream initiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Steven Fleishman initiated Enable Midstream with a Peer Perform and a $16 price target.
09/13/16
FBCO
09/13/16
DOWNGRADE
Target $16
FBCO
Neutral
Enable Midstream downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst John Edwards downgraded Enable Midstream to Neutral citing year-to-date share strength and maintained its $16 price target.
08/08/16
RBCM
08/08/16
NO CHANGE
RBCM
CenterPoint Energy weakness overdone, says RBC Capital
RBC Capital analyst Insoo Kim says that Centerpoint's (CNP) stock may have fallen Friday due to the company's weaker than expected results and its decision not to pursue a REIT structure. The analyst remains upbeat on the company's outlook in the absence of a REIT conversion. Kim continues to believe that Centerpoint's potential sale or spin of its Enable Midstream (ENBL) stake is a positive catalyst for it. Kim keeps a $26 price target and Outperform rating on the shares.
HPQ HP Inc.
$15.95

-0.05 (-0.31%)

11/23/16
JEFF
11/23/16
DOWNGRADE
Target $16.75
JEFF
Hold
HP Inc. downgraded to Hold from Buy at Jefferies
Jefferies analyst James Kisner downgraded HP Inc. to Hold with a $16.75 price target following the company's Q4 results. The analyst cites valuation and secular challenges for the downgrade.
08/25/16
EVER
08/25/16
NO CHANGE
EVER
Micron has positive read through from HP statements, says Evercore ISI
After Hewlett-Packard (HPQ) said, "We are seeing on the horizon some shortages, particularly around LCDs, DRAM, and flash memory.," Evercore ISI analyst C.J. Muse says that the statement is positive for Micron. The analyst keeps a $16 price target and Buy rating on Micron.
08/25/16
MAXM
08/25/16
DOWNGRADE
Target $15
MAXM
Hold
HP Inc. downgraded to Hold on pressured printing margins at Maxim
As previously reported, Maxim analyst Nehal Chokshi downgraded HP Inc. to Hold from Buy and lowered his price target to $15 from $17, saying that his analysis points to sustained printing supplies pricing pressure despite the refresh of its printer hardware. Chokshi added that he expects the company to lower its FY17 earnings guidance at its Securities Analyst Meeting in October.
10/14/16
BMUR
10/14/16
NO CHANGE
Target $18
BMUR
Buy
HP Inc. new business model conservative, says Brean Capital
Brean Capital analyst Ananda Baruah attended the HP, Inc. analyst day and said although it didn't hold any surprises, he believes the company's new long-term business model remains conservative. The analyst said if the company can execute its model its revenue growth will have to be stronger than stated and its guidance must be conservative. Baruah reiterated his Buy rating and $18 price target on HP, Inc. shares.
HPE HP Enterprise
$22.87

-0.25 (-1.08%)

11/23/16
SBSH
11/23/16
NO CHANGE
Target $27
SBSH
Buy
HP Enterprise price target raised to $27 from $25 at Citi
Citi analyst Jim Suva raised his price target for HP Enterprise to $27 and keeps a Buy rating on the shares following the company's Q4 results. The stock is trading at a "big" discount to peers and its outlook is unchanged, Suva tells investors in a research note.
11/23/16
UBSW
11/23/16
NO CHANGE
Target $26
UBSW
Buy
HP Enterprise remains inexpensive, says UBS
UBS analyst Steven Milunovich said HP Enterprise shares remain inexpensive following Q4 results. The analyst cited improving growth and low valuation despite disappointing declines in servers, storage, and networking. The positives were improved margins and solid outlook. Milunovich reiterated his Buy rating and raised his price target to $26 from $24.50 on HP Enterprise shares.
11/23/16
OPCO
11/23/16
NO CHANGE
Target $25
OPCO
Outperform
Oppenheimer remains positive on HP Enterprise after results
Oppenheimer analyst Ittai Kidron notes that HP Enterprise (HPE) reported mixed results and says the macro and secular strains experienced by Cisco (CSCO) seem to have impacted the company as well. Nonetheless, the analyst believes HP Enterprise continues on its march to unlock value, and its two spin-offs remain on track. While he is positive long term and believes valuation is attractive, Kidron sees limited near-term upside given the challenges in the core EG business. The analyst reiterates an Outperform rating and $25 price target on HP Enterprise's shares.
11/23/16
BERN
11/23/16
NO CHANGE
BERN
HP Enterprise weakness creates buying opportunity, says Bernstein
After HP Enterprise reported lower than expected revenue but in-line EPS, Bernstein analyst A.M. Sacconaghi, Jr. says that the company's CSC and Enterprise Services unit continue to deliver good results. The analyst continues to believe that "the stock remains truly inexpensive," and that the weakness in the name creates a buying opportunity. Sacconaghi keeps a $24.50 price target and an Outperform rating on the shares.
NMBL Bought by HPE
$9.24

0.15 (1.65%)

10/03/16
SUSQ
10/03/16
NO CHANGE
Target $12
SUSQ
Positive
Nimble Storage well positioned to gain market share, says Susquehanna
Susquehanna analyst Mehdi Hosseini believes Nimble Storage remains well positioned to continue to gain market share with its dual faceted approach and material operating leverage on the horizon in 2018. Hosseini reiterated his Positive rating and $12 price target on Nimble Storage shares.
09/29/16
WELS
09/29/16
UPGRADE
WELS
Outperform
Nimble Storage upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Maynard Um upgraded Nimble Storage to Outperform saying the risk/reward is favorable at current valuation levels. A "strong pipeline" for Nimble's all-flash array should drive revenue acceleration in FY18 and multiple expansion, Um tells investors in a research note. The analyst raised his price target range for the shares to $10-$11 from $9-$10.
11/23/16
MAXM
11/23/16
NO CHANGE
Target $12
MAXM
Buy
Nimble Storage shows multiple signs of turnaround progress, says Maxim
Maxim analyst Nehal Chokshi said multiple metrics, including 5K bookings acceleration and SME bookings acceleration, indicate Nimble Storage's turnaround is progressing, which he believes will become more apparent in next quarter. The company's Lenovo deal and R&D pipeline give him further confidence that Nimble will be a long-term storage player, added Chokshi, who keeps a Buy rating and $12 price target on the shares, which are down about 13% to $8.05 in pre-market trading.
11/23/16
SUSQ
11/23/16
NO CHANGE
Target $12
SUSQ
Positive
Nimble Storage takeover prospects cannot be overlooked, says Susquehanna
Susquehanna analyst Mehdi Hosseini noted Nimble Storage reported relatively in-line Q3 results and guidance. The analyst said that was enough to keep his framework intact as he believes the company is well positioned to continue gaining market share with its Hybrid/All-Flash portfolio. Hosseini also said its prospects as a takeover target for a large player should not be overlooked. Hosseini reiterated his Positive rating and $12 price target on Nimble Storage shares.

TODAY'S FREE FLY STORIES

13:20
06/27/17
06/27
13:20
06/27/17
13:20
General news
Treasury Action: yields extended their surge »

Treasury Action: yields…

$NSD

NASDAQ Market Internals

13:17
06/27/17
06/27
13:17
06/27/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
06/27/17
06/27
13:16
06/27/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLF

Financial Select Sector

$24.27

0.25 (1.04%)

, XLK

Technology Select Sector SPDR

$55.52

-0.48 (-0.86%)

13:15
06/27/17
06/27
13:15
06/27/17
13:15
Technical Analysis
Technical View: S&P 500 mid-session chart update »

The S&P 500 (SPX) did…

XLF

Financial Select Sector

$24.27

0.25 (1.04%)

XLK

Technology Select Sector SPDR

$55.52

-0.48 (-0.86%)

SPY

SPDR S&P 500 ETF Trust

$242.76

-0.53 (-0.22%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$153.59

-1.48 (-0.95%)

13:08
06/27/17
06/27
13:08
06/27/17
13:08
Hot Stocks
Facebook reaches two billion users, Zuckerberg says »

Facebook CEO Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

AVAV

AeroVironment

$30.97

0.2 (0.65%)

13:07
06/27/17
06/27
13:07
06/27/17
13:07
Conference/Events
AeroVironment management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 03

    Jul

  • 04

    Jul

  • 05

    Jul

CBI

CB&I

$19.00

4.6 (31.94%)

13:05
06/27/17
06/27
13:05
06/27/17
13:05
Options
CB&I call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$109.93

-0.12 (-0.11%)

13:05
06/27/17
06/27
13:05
06/27/17
13:05
Hot Stocks
Quest Diagnostics announces intent to acquire CCHC outreach lab business »

Quest Diagnostics …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

FOX

21st Century Fox

$27.62

0.69 (2.56%)

, FOXA

21st Century Fox

$28.04

0.85 (3.13%)

12:57
06/27/17
06/27
12:57
06/27/17
12:57
Hot Stocks
FOX Sports partners with Facebook to stream Champions League soccer »

Twenty-First Century…

FOX

21st Century Fox

$27.62

0.69 (2.56%)

FOXA

21st Century Fox

$28.04

0.85 (3.13%)

FB

Facebook

$153.59

-1.48 (-0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

DHXM

DHX Media

$4.15

-0.0367 (-0.88%)

12:56
06/27/17
06/27
12:56
06/27/17
12:56
Conference/Events
DHX Media management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

IVZ

Invesco

$35.01

-0.005 (-0.01%)

12:55
06/27/17
06/27
12:55
06/27/17
12:55
Conference/Events
Invesco management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

FDX

FedEx

$215.36

-0.0025 (-0.00%)

12:52
06/27/17
06/27
12:52
06/27/17
12:52
Periodicals
TNT Express says hit with 'interference' with some of its systems, ABC News says »

A spokesman for TNT…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jul

FDX

FedEx

12:50
06/27/17
06/27
12:50
06/27/17
12:50
Periodicals
FedEx 'operating normally' after functionality issues, Reuters reports »

A spokeswoman for FedEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jul

THC

Tenet

$19.43

0.6587 (3.51%)

12:50
06/27/17
06/27
12:50
06/27/17
12:50
Options
3K Tenet Healthcare Jul 20 calls trade for 88c »

3K Tenet Healthcare Jul…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

AMZN

Amazon.com

$993.98

-9.76 (-0.97%)

, WFM

Whole Foods

$42.69

-0.255 (-0.59%)

12:48
06/27/17
06/27
12:48
06/27/17
12:48
Hot Stocks
Kroger CEO: Whole Foods 'great fit' for Amazon »

Speaking in a CNBC…

AMZN

Amazon.com

$993.98

-9.76 (-0.97%)

WFM

Whole Foods

$42.69

-0.255 (-0.59%)

KR

Kroger

$22.97

0.355 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

SMSMY

Sims Metal

$10.30

-0.03 (-0.29%)

12:47
06/27/17
06/27
12:47
06/27/17
12:47
Upgrade
Sims Metal rating change  »

Sims Metal upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
06/27/17
06/27
12:45
06/27/17
12:45
General news
Breaking General news story  »

Federal Reserve Chair…

12:45
06/27/17
06/27
12:45
06/27/17
12:45
Conference/Events
Federal Reserve Board Chair Yellen speaks on global economic issues »

Federal Reserve Board…

DD

DuPont

$80.85

-0.31 (-0.38%)

, DOW

Dow Chemical

$63.30

-0.27 (-0.42%)

12:43
06/27/17
06/27
12:43
06/27/17
12:43
Periodicals
Mexico's Cofece grants conditional approval of DuPont-Dow tie-up, Reuters says »

Mexico's Federal…

DD

DuPont

$80.85

-0.31 (-0.38%)

DOW

Dow Chemical

$63.30

-0.27 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

TGT

Target

$52.22

0.74 (1.44%)

, AMZN

Amazon.com

$993.98

-9.76 (-0.97%)

12:41
06/27/17
06/27
12:41
06/27/17
12:41
Periodicals
Target prices next-day delivery service test $1 below Amazon's, StarTribune says »

Target (TGT), which just…

TGT

Target

$52.22

0.74 (1.44%)

AMZN

Amazon.com

$993.98

-9.76 (-0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

CBI

CB&I

$19.08

4.68 (32.50%)

12:34
06/27/17
06/27
12:34
06/27/17
12:34
Hot Stocks
CB&I says court vindicates position in lawsuit against Westinghouse »

CB&I issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:30
06/27/17
06/27
12:30
06/27/17
12:30
General news
Treasury 5-year auction outlook: the auction should go well »

Treasury 5-year auction…

MSFT

Microsoft

$70.53

-0.68 (-0.95%)

, BOX

Box

$19.45

0.31 (1.62%)

12:25
06/27/17
06/27
12:25
06/27/17
12:25
Hot Stocks
Box, Microsoft announce expanded cloud partnership »

Box (BOX) and Microsoft…

MSFT

Microsoft

$70.53

-0.68 (-0.95%)

BOX

Box

$19.45

0.31 (1.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

SMSMY

Sims Metal

$10.30

-0.03 (-0.29%)

12:24
06/27/17
06/27
12:24
06/27/17
12:24
Upgrade
Sims Metal rating change  »

Sims Metal upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

12:17
06/27/17
06/27
12:17
06/27/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.